On February 16, 2022, FDA published a compounding danger inform describing the prospective pitfalls associated with at-home use of compounded ketamine nasal spray and several adverse occasion reviews. The February 2022 compounding danger inform also delivered information regarding Spravato, which can be matter to the Risk Analysis and Mitigation St